Elevance Health Inc. (ELV)
NYSE • Healthcare
Last close at October 13, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Elevance Health Inc. keeps $3 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 21
in 7 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Elevance Health topped expectations on both the top and bottom line in the second fiscal quarter of 2026, reported July 15, as adjusted EPS of $7.45 beat the $6.21 estimate by 20.0% and revenue of about $50.5 billion topped the $48.9 billion consensus by 1.9%. Revenue rose 1.4% from about $49.8 billion a year earlier, with gross margin near 89.1% and operating margin around 4.1%, while net income fell 16.1% to roughly $1.5 billion from about $1.7 billion a year earlier. The company generated operating cash flow of about $1.9 billion, repurchased about $234 million of stock and paid about $373 million in dividends. Consensus for the next period calls for EPS of $4.79 on revenue of $49.26 billion.
Next report — what to expect
Elevance Health Inc. (ELV) reports on October 21, 2026. Wall Street is looking for consensus EPS of $4.66 on consensus revenue of $49.30 billion. For trailing context, revenue rose +1.4% year over year last quarter. ELV has beaten EPS in 6 of 8 most recent quarters.
About Elevance Health Inc.
Elevance Health Inc. provides health-benefits and care-management services in the healthcare sector, centered on medical plans and related care solutions. Its shares trade on the NYSE under ELV, and the company generated $199.1 billion in revenue in FY2025 through health plans and care programs that support members' access to care.
Today's Snapshot
ELV closed 0.8% above yesterday's close, outperforming a weaker sector. Volume was about half as much again as its usual level. Barclays, an investment bank, raised Elevance Health’s price target to $469.
Trading Volume
Above 10d avg 1.2M
1.7M
vs S&P 500 Today
Outperforming Market
+0.77%
Updated: October 13, 2026 at 20:27 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$371.36 - $408.06Buy
- RSI (14)65.71Neutral
- Stochastic %K (14, 3, 3)89.19Sell
- MACD Level (12, 26)3.10Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.